Texas court awards $41m to US biotech
Japan-based pharma company must pay for infringment | Drug was recently approved for breast cancer treatment by EU.
BGI wins $333m in DNA patent suit with Illumina
Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Janssen seeks to halt generic schizophrenia drug
Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate).
China accepts cluster of complaints under new patent linkage law
The China National Intellectual Property Administration has accepted its first set of drug patent linkage complaints since the introduction of a new patent law in June 2021.
Pfizer fights approval of generic Ibrance
Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
WHO issues fresh warning over fake COVID vaccines
The World Health Organization has identified counterfeit versions of the Covishield vaccine in India and Uganda.
Chinese doctor enjoined in trade secrets lawsuit
A US federal court has upheld a preliminary injunction against a Chinese doctor accused of stealing trade secrets from US heart device manufacturer AtriCure.
WTO declines to waive TRIPS provisions for COVID-19 drugs
Representatives of South Africa and India have again tried and failed to persuade the World Trade Organization to waive IP rights related to COVID-19 treatments and vaccinations.
US customs seize 100k fake N95s from Hong Kong
US customs officials at John F Kennedy International Airport in New York have seized 100,000 counterfeit 3M N95 masks imported from Hong Kong.
India approves COVID-19 vaccines ahead of huge rollout
India has granted emergency approval to COVID-19 vaccines developed by AstraZeneca and Oxford University and one from the state-run institute Bharat Biotech, ahead of a huge immunisation drive that is planned to begin this week.